Sanofi has signed an agreement with ImmuNext, a biopharmaceutical company headquartered in Lebanon, New Hampshire, to develop an antibody with potential to treat a range of autoimmune diseases including lupus and multiple sclerosis.

Under the agreement, ImmuNext will grant Sanofi an exclusive, worldwide license to develop and commercialize INX-021, a CD40L monoclonal antibody in preclinical development for use in various autoimmune diseases. The companies will also initiate a research collaboration to support clinical trials. Potential milestone payments to ImmuNext could total more than $500 million. ImmuNext is also eligible to receive tiered royalties up to double digits on sales of products.

Source: ImmuNext